Bracco Imaging S.p.A.
Bracco Imaging S.p.A. is a diagnostic-imaging company based in Milan, Italy, that develops and supplies contrast agents, radiopharmaceuticals, medical devices, and related services to healthcare systems globally. With over 3,800 employees and a presence in more than 100 countries, its products are integral to CT, MRI, ultrasound, and nuclear medicine workflows. The company’s public internet footprint (AS211943) is a minor corporate infrastructure signal, secondary to its regulated medical role.
Why It Matters
Bracco Imaging impacts healthcare operations by supplying regulated imaging agents and technologies that influence scan quality and diagnostic workflow. A regulatory or supply disruption can delay exams, alter protocols, or increase costs; a new partnership or approval can shift clinical practice. The public internet registry signal is a secondary infrastructure indicator that may help assess corporate network changes but does not directly measure product availability.
What Public Sources Show
Bracco Imaging S.p.A. is a Milan-based company that supplies contrast agents, radiopharmaceuticals, and related technologies to radiology departments worldwide. Its products sit at the intersection of imaging protocols, contrast enhancement, and scan interpretation, making the company a critical node in diagnostic medicine. A change in its product approvals, supply continuity, or research direction can ripple through hospital workflows and patient outcomes.
Official company pages describe a portfolio spanning X-ray/CT, MRI, ultrasound, nuclear medicine, and interventional cardiology, with more than 3,800 employees supporting healthcare systems in over 100 countries. An Italian government publication confirms its legal identity at via E. Folli 50 in Milan. Public internet routing records associate the company with autonomous system AS211943 and a single announced IPv4 route, hinting at a small corporate network footprint.
The company’s operating surface includes regulated pharmaceuticals, medical devices, injectors, and imaging software tied to regulatory approvals in each market. Research-and-development sites in Italy, Switzerland, the United States, and China signal a sustained innovation effort, with about 10% of reference turnover invested in R&D.
Strategic partnerships—most recently a multi-year alliance with NYU Langone Health and an AI-driven MRI agreement with Subtle Medical—show a deliberate push into advanced image analysis and clinical AI.
The material control surface is the portfolio of approved contrast agents and radiopharmaceuticals. Manufacturing continuity, pharmacovigilance obligations, and country-specific labeling determine where and how the products can be used. The company’s internet registry presence (AS211943) is a secondary indicator of corporate infrastructure, not a measure of product availability.
Readers should monitor regulatory announcements for label changes, new indications, or safety communications. Manufacturing-site or batch-release disruptions could affect imaging capacity. The conversion of research alliances into commercially deployed products will signal competitive shifts.
No standalone audited annual report for Bracco Imaging S.p.A. was verified in this assessment, so financial-scale claims rely on the official company profile. The routing evidence is limited to ASN registration and a single route; it does not reveal internal network use. Product availability varies by jurisdiction, and public sources do not shed light on private supply contracts.
This profile draws on official Bracco.com pages, a RIPE RDAP record, a mirrored Whois service, and a notice in Italy’s Gazzetta Ufficiale. All sources are low-risk official publications as of mid-2026.
Operating Surface
Bracco Imaging operates in regulated diagnostic imaging, supplying contrast agents, microbubbles, radiopharmaceutical agents, injectors, software, and related services used by hospitals and radiology professionals. Its operating surface includes regulatory approvals across countries, a global R&D and manufacturing network, and strategic clinical-AI partnerships. A public internet registry footprint (AS211943) exists but is secondary to its medical-imaging role.
The company’s products sit at the convergence of imaging protocols, contrast enhancement, scanner workflow, and clinical interpretation. Changes in approvals, availability, safety labeling, manufacturing continuity, AI partnerships, or corporate network reachability can cascade to radiology departments, procurement decisions, and patient diagnostic confidence, making it a relevant entity for healthcare-infrastructure tracking.
Watchpoints
Bracco Imaging’s strategic value lies in its dual role: a healthcare provider of critical contrast agents and an active partner in AI-enabled imaging research. The convergence of regulatory oversight, manufacturing complexity, and clinical integration creates a wide impact surface. The internet routing presence is a lagging indicator of corporate infrastructure, not a primary operational signal.
Track new regulatory approvals, label changes, and safety alerts by jurisdiction; monitor manufacturing-site announcements for supply continuity; watch for commercial deployment of AI research agreements with NYU Langone and Subtle Medical; and note any expansion or withdrawal of routes under AS211943.
Standalone audited financials for Bracco Imaging S.p.A. are not verified; the current assessment relies on official company metrics. Internal network use and traffic are opaque. Country-specific product availability requires local regulatory source verification before making market-specific claims.
Sources
- Registry RDAP / WHOIS record - public-source identity and registry context for Bracco Imaging S.p.A..
- bracco.com - Identifies Bracco Imaging as a global diagnostic-imaging company with a portfolio of contrast agents, CEUS microbubbles, molecular-imaging/PET agents, specialized medical devices and related services, and states more than 3,800 employees and support for healthcare systems in more than 100 countries.
- bracco.com - Describes Bracco Group business areas and Bracco Imaging's diagnostic-imaging portfolio across contrast agents, X-ray/CT, MRI, CEUS, molecular imaging, devices and services.
- bracco.com - Shows Bracco's diagnostic-imaging modality coverage across X-ray/CT, MRI, ultrasound, nuclear medicine and interventional cardiology, and notes market-by-market availability.
- bracco.com - States that Bracco Group invests approximately 10% of reference turnover in R&D and describes research centers, imaging-agent development, sustainable processes and AI-related work.
- bracco.com - Describes Bracco research and operating facilities, including Geneva and Ivrea sites and additional research facilities across the UK, Switzerland, Germany, United States and China.
- gazzettaufficiale.it - Official Italian publication identifies BRACCO IMAGING S.P.A., registered office at via E. Folli 50 in Milan, fiscal code 07785990156, and Bracco Imaging SpA as holder in a medicinal-product authorization variation notice.
- Registry RDAP / WHOIS record - Mirrors RIPE whois and routing details for AS211943/BRACCO-AS, including org name Bracco Imaging S.p.A., ORG-BIS28-RIPE, LIR type, upstream imports/exports and visible IPv4 route 185.85.252.0/24.
- bracco.com - Announces a 20 April 2026 strategic alliance between Bracco Imaging and NYU Langone Health through a multi-year Master Research Agreement focused on MRI, photon-counting CT, targeted ultrasound and AI-enabled PET/CT and MRI image analysis.
- bracco.com - Announces a 21 September 2023 global agreement between Bracco Imaging S.p.A. and Subtle Medical for AI-powered image acquisition in contrast-enhanced MRI.
- bracco.com - Describes Blue Earth Diagnostics as part of the Bracco Group following a 2019 acquisition by Bracco Imaging and explains its molecular-imaging and PET radiopharmaceutical role.
